Treatment with metformin in twelve patients with Lafora disease

BACKGROUND: Lafora disease (LD) is a rare, lethal, progressive myoclonus epilepsy for which no targeted therapy is currently available. Studies on a mouse model of LD showed a good response to metformin, a drug with a well known neuroprotective effect. For this reason, in 2016, the European Medicine...

Descripción completa

Detalles Bibliográficos
Autores principales: Bisulli, Francesca, Muccioli, Lorenzo, d’Orsi, Giuseppe, Canafoglia, Laura, Freri, Elena, Licchetta, Laura, Mostacci, Barbara, Riguzzi, Patrizia, Pondrelli, Federica, Avolio, Carlo, Martino, Tommaso, Michelucci, Roberto, Tinuper, Paolo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6588886/
https://www.ncbi.nlm.nih.gov/pubmed/31227012
http://dx.doi.org/10.1186/s13023-019-1132-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6588886/
https://www.ncbi.nlm.nih.gov/pubmed/31227012
http://dx.doi.org/10.1186/s13023-019-1132-3

Ejemplares similares